Business Wire

SHARJAH-GOVERNMENT

Share
Sir Bu Nair Island, a Safe Haven for Rare Creatures

Around midnight on June 1, a hawksbill turtle landed on the Sir Bu Nair Island. It’s one of the many that began arriving three months ago to nest on the island, bringing the number of nests to more than 300 spread across 27 beaches. The hawksbill turtle lays between 90 to 110 eggs and quietly returns to the sea, leaving eggs to hatch in 50 to 70 days. Part of Sharjah, Sir Bu Nair is situated around 110 km north off the Emirate’s coast.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220606005699/en/

Declared a nature reserve by a government decree, the island is one of the most important breeding grounds for the endangered hawksbill turtle and features on the International Union for Conservation of Nature list.

The enchanting island, 13 sq km in size, is home to the sooty seagulls (Abu Sannin) and other terns who make thousands of nests in its red soil. Sharjah has strict laws in place to protect all living creatures on the island. Sir Bu Nair is rich in rare green sea turtles, deer, hedgehogs and reptiles. It has also recorded the discovery of the red coat fish.

Rich history

Sir Bu Nair Island has long been preserved in the region’s collective memory of historical events. The British established, during their presence in the region, the first railway in the Emirates, whose relics remain on one side of the beach under the sea.

The island is also known for the sweetness of its waters, which is also fabled to cure rare diseases.

Pottery vessels have been found on the island dating back to the Iron Age, i.e. about 3,500 years ago confirming the continuation of marine activity on the island during the past 35 centuries. There is a cemetery on the island that is known to contain the remains of a number of divers and miners, which represents an important stage in the history of the development of the people living on the banks of the Arabian Gulf.

Mars Island

The island is also known as Al-Jazirah Al-Hamra because of its red terrain and is often compared to the planet Mars. It’s rich in minerals, including sulfur and iron oxide. In the past, railways were used to transport minerals to ships for exporting abroad. Some mines survive to this day.

Known for its sandy beaches and its pristine waters, Sir Bu Nair and its surroundings are rich in coral and marine life, boasting more than 76 types of fish and 40 types of coral reefs.

Emirati poets have long described Sir Bu Nair as “the tear that fell in the waters of the Gulf.” The people of Sharjah have a strong affinity with the island thanks to their historical love of the sea and seafaring traditions. The island had been the seat of generations of pearldivers and fishermen.

International importance

The Sir Bu Nair reserve enjoys strategic global importance and is included in the International Convention on Wetlands because of its rich marine life. It’s included in the preliminary list of UNESCO World Heritage Sites, and an international agreement on the protection and management of sea turtles in the Indian Ocean and Southeast Asia.

HH Sheikh Sultan bin Ahmed Al Qasimi, Deputy Ruler of Sharjah, attended the 22nd Sir Bu Nair Festival, held on June 3-4 to highlight the island's environmental and touristic importance and consolidate the Emirati relationship with their environment and heritage.

Source: AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye